Nodular Lymphocyte-Predominant Hodgkin's Lymphoma (NLPHL)
Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma that accounts for approximately 5% of all cases. With a team of distinguished scientists at our helm, we specialize in developing revolutionary NLPHL therapies for global pharmaceuticals.
Introduction to NLPHL
Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare lymphoma with an incidence of 0.1-0.2 per 100,000 people per year. Compared to classical Hodgkin's lymphoma, NLPHL has distinct pathological features. It typically presents as a painless enlargement of lymph nodes, most commonly in the neck, armpits, or groin. Unlike classical Hodgkin's lymphoma, NLPHL often has a more indolent course with a favorable prognosis.
Pathogenesis of NLPHL
- The distinguishing feature of NLPHL is the presence of L&H cells, which are thought to be the neoplastic cells responsible for the development of the disease. These cells express CD20, a B-cell marker, and often exhibit aberrant expression of other B-cell markers, including CD79a and CD22.
- Genetic studies have revealed recurrent chromosomal abnormalities in NLPHL, including rearrangements of the immunoglobulin heavy chain gene (IGH) and amplification of the BCL6 gene. These genetic alterations may contribute to the dysregulation of B-cell development and survival, leading to the accumulation of L&H cells.
Fig.1 Relative survival estimates for NLPHL. (Kalashnikov, Ilja, et al., 2021)Therapeutics Development of NLPHL
- Targets of NLPHL Therapy Development
Identifying specific molecular targets in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma (NLPHL) has opened up avenues for the development of targeted therapies. These targets offer opportunities to disrupt the signaling pathways crucial for the survival and proliferation of L&H cells. Several key targets have been explored:
- CD20 is a cell surface protein expressed on B cells, including L&H cells in NLPHL.
- BCL6 is a transcriptional repressor that plays a critical role in B-cell development and differentiation. Aberrant expression of BCL6 has been observed in NLPHL, suggesting its involvement in the pathogenesis of the disease.
- Types of NLPHL Therapy Development
Therapeutic Antibodies
Monoclonal antibodies targeting CD20 have been investigated as potential therapeutic options for NLPHL. Rituximab has shown promising results in treating NLPHL, leading to improved response rates and long-term outcomes.
Small Molecule Drugs
Small molecule inhibitors targeting BCL6, such as RI-BPI, are being investigated as potential therapeutic options for NLPHL. These inhibitors aim to disrupt the aberrant BCL6-mediated signaling and promote apoptosis of L&H cells.
Our Services
At our company, we stand tall, adorned with the pride of offering an exquisite array of meticulously tailored research solutions that effortlessly harmonize with the distinctive requirements of biology experts. Whether the quest at hand pertains to diagnostics development or the elusive realms of therapy development, our collective of brilliant minds intertwines seamlessly with yours, forging a collaborative bond that births a meticulously crafted research plan, exquisitely customized to align with your unique objectives.
Platforms of NLPHL Therapy Development
Over the years, we have been committed to the construction of animal model development platforms that can meet your NLPHL preclinical research. From drug safety assessments to pharmacokinetic analyses, we have the ability to provide diverse animal species to support any of your needs and accelerate the development of NLPHL therapies.
Animal Models of NLPHL
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Kalashnikov, Ilja, et al. "Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study." Blood cancer journal 11.12 (2021): 203.
- Weniger, Marc A., and Ralf Küppers. "Molecular biology of Hodgkin lymphoma." Leukemia 35.4 (2021): 968-981.
- Ansell, Stephen M. "Hodgkin lymphoma: diagnosis and treatment." Mayo Clinic Proceedings. Vol. 90. No. 11. Elsevier, 2015.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.